重药控股：预计2025年上半年净利润同比增长9.2%—26%

Group 1 - The company expects a net profit attributable to shareholders of 260 million to 300 million yuan for the period from January 1, 2025, to June 30, 2025, representing a year-on-year growth of 9.2% to 26% [1] - The net profit after deducting non-recurring gains and losses is projected to be between 250 million and 280 million yuan, indicating a year-on-year increase of 14.39% to 28.12% [1] - The basic earnings per share are estimated to be between 0.15 yuan and 0.17 yuan [1]